March 3, 2026Open Access

Correction: Non-superagonist CD28-based dual-signal T cell engager targeting KK-LC-1 enhances antitumor efficacy

Key Points

Enhanced antitumor efficacy is observed with the dual-signal T cell engager.
This approach targets KK-LC-1, leading to improved immune response against tumors.
Assessment of the dual-signal engager shows promising results in tumor models.
Further clinical evaluations are needed to confirm these findings in humans.

Abstract

Chen T, Wang Y, Chen X, et al. Non-superagonist CD28-based dual-signal T cell engager targeting KK-LC-1 enhances antitumor efficacy. J Immunother Cancer 2026;14:e013246. https://doi.org/10.1136/jitc-2025-013246

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Journals

SHILAP Revista de lepidopterología

Journal for ImmunoTherapy of Cancer

Actions

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Correction: Non-superagonist CD28-based dual-signal T cell engager targeting KK-LC-1 enhances antitumor efficacy

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Journals

Actions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study